Motoko Y. Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Motoko Y. Kimura has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Kiyoshi Hirahara
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
37 shared publications - Toshinori Nakayama
Department of Immunology, Graduate School of Medicine Chiba University Chiba Japan
37 shared publications - Ami Aoki
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
35 shared publications - Masahiro Kiuchi
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
35 shared publications - Atsushi Onodera
Institute for Advanced Academic Research, Chiba University, Chiba, Japan
34 shared publications - Ichita Hasegawa
Department of Experimental Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan
34 shared publications
Latest Publications
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eadx9864
Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eadx9864
Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.
- Open Access
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eadw1038
CD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells
Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eadw1038
Open AccessCD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells
Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.
- 11 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6778) , eadp0714
Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4 + T cells
CD4 + tissue-resident memory T (T RM ) cells contribute to host defense and to the pathogenesis of chronic inflammatory diseases, but the molecules that direct their differentiation are unknown. We found that the transcription factor hepatic leukemia factor (HLF) could direct the tissue residency program and function of CD4 + T RM cells. HLF simultaneously up-regulated tissue retention receptors, down-regulated tissue egress receptors, and promoted proinflammatory CD4 + T RM cells by inducing Bhlhe40 , and all of these processes were associated with changes in chromatin accessibility. Genetic deletion of Hlf inhibited CD4 + T RM cell generation and ameliorated airway tissue inflammation in vivo. HLF + CD4 + T RM cells isolated from inflamed airway tissue in humans had a tissue residency signature and expressed inflammatory cytokines. We conclude that HLF may act as a central regulator of proinflammatory CD4 + T RM cell development and function.
- 11 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6778) , eadp0714
Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4 + T cells
CD4 + tissue-resident memory T (T RM ) cells contribute to host defense and to the pathogenesis of chronic inflammatory diseases, but the molecules that direct their differentiation are unknown. We found that the transcription factor hepatic leukemia factor (HLF) could direct the tissue residency program and function of CD4 + T RM cells. HLF simultaneously up-regulated tissue retention receptors, down-regulated tissue egress receptors, and promoted proinflammatory CD4 + T RM cells by inducing Bhlhe40 , and all of these processes were associated with changes in chromatin accessibility. Genetic deletion of Hlf inhibited CD4 + T RM cell generation and ameliorated airway tissue inflammation in vivo. HLF + CD4 + T RM cells isolated from inflamed airway tissue in humans had a tissue residency signature and expressed inflammatory cytokines. We conclude that HLF may act as a central regulator of proinflammatory CD4 + T RM cell development and function.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eadp0849
Lipolysis-microlipophagy cascade regulated by adipose triglyceride lipase drives pathogenic adaptive type 2 immunity
A unique subpopulation of memory T helper 2 (T H 2) cells expressing the interleukin-33 (IL-33) receptor ST2 drives allergic disease pathogenesis. However, the immunometabolic mechanisms that induce ST2 hi memory T H 2 cells remain unclear. We show using a mouse model of chronic allergic airway inflammation that long-chain unsaturated fatty acids (LC-UFAs) accumulate in the inflammatory milieu during chronic airway inflammation. Activated T H 2 cells take up LC-UFAs, transiently store them in lipid droplets (LDs), and catabolize LDs through lipolysis and microlipophagy. LD catabolism regulated by adipose triglyceride lipase (ATGL) activates peroxisome proliferator–activated receptor γ (PPARγ). PPARγ then binds the Il1rl1 locus encoding ST2 and induces ST2 hi effector and memory T H 2 cells. In eosinophilic chronic rhinosinusitis, CD45RO + CD4 T cells in nasal polyps exhibit microlipophagy and an accessible IL1RL1 enhancer, indicating that these mechanisms are conserved in humans. Thus, the storage and catabolism of inflammatory milieu–derived LC-UFAs direct pathogenic adaptive type 2 immunity, offering potential therapeutic strategies for persistent allergic inflammation.
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eadp0849
Lipolysis-microlipophagy cascade regulated by adipose triglyceride lipase drives pathogenic adaptive type 2 immunity
A unique subpopulation of memory T helper 2 (T H 2) cells expressing the interleukin-33 (IL-33) receptor ST2 drives allergic disease pathogenesis. However, the immunometabolic mechanisms that induce ST2 hi memory T H 2 cells remain unclear. We show using a mouse model of chronic allergic airway inflammation that long-chain unsaturated fatty acids (LC-UFAs) accumulate in the inflammatory milieu during chronic airway inflammation. Activated T H 2 cells take up LC-UFAs, transiently store them in lipid droplets (LDs), and catabolize LDs through lipolysis and microlipophagy. LD catabolism regulated by adipose triglyceride lipase (ATGL) activates peroxisome proliferator–activated receptor γ (PPARγ). PPARγ then binds the Il1rl1 locus encoding ST2 and induces ST2 hi effector and memory T H 2 cells. In eosinophilic chronic rhinosinusitis, CD45RO + CD4 T cells in nasal polyps exhibit microlipophagy and an accessible IL1RL1 enhancer, indicating that these mechanisms are conserved in humans. Thus, the storage and catabolism of inflammatory milieu–derived LC-UFAs direct pathogenic adaptive type 2 immunity, offering potential therapeutic strategies for persistent allergic inflammation.
- Open Access
- 23 September 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (21)
CCL5 paradoxically regulates glomerular injury by skewing macrophage polarization
Glomerular inflammation and podocyte loss are the hallmarks of chronic kidney disease (CKD) progression. Understanding how podocytes and their microenvironment regulate inflammation is critical for developing effective therapies. In this study, we identified C-C chemokine ligand 5 (CCL5) as an inflammatory mediator elevated in injured podocytes, based on analyses of both human kidney biopsies and mouse models of CKD. We discovered that CCL5 exerts paradoxical effects in nephropathy; while it protects podocytes in vitro, it exacerbates glomerular injury in vivo. Recombinant CCL5 and podocyte-specific CCL5 overexpression promoted cell survival and reduced apoptosis in cultured podocytes. However, in adriamycin-induced nephropathy, CCL5 worsened glomerular injury, increasing proteinuria, glomerulosclerosis, and podocyte loss. Bone marrow (BM) transplantation experiments revealed that CCL5 in BM-derived cells — not kidney-resident cells — drove disease progression. CCL5 deficiency in BM-derived cells conferred protection by increasing reparative M2 macrophages, whereas endogenous CCL5 promoted M1 polarization, inhibited M2 differentiation, and triggered M2-to-M1 transition. These findings demonstrate that while CCL5 supports podocyte survival, its expression in BM-derived cells promotes inflammatory macrophage phenotypes and glomerular injury. The harmful immune effects of CCL5 in BM-derived cells outweigh its podocyte-protective role, highlighting the importance of cell-targeted strategies to mitigate kidney damage.
- 23 September 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (21)
Open AccessCCL5 paradoxically regulates glomerular injury by skewing macrophage polarization
Glomerular inflammation and podocyte loss are the hallmarks of chronic kidney disease (CKD) progression. Understanding how podocytes and their microenvironment regulate inflammation is critical for developing effective therapies. In this study, we identified C-C chemokine ligand 5 (CCL5) as an inflammatory mediator elevated in injured podocytes, based on analyses of both human kidney biopsies and mouse models of CKD. We discovered that CCL5 exerts paradoxical effects in nephropathy; while it protects podocytes in vitro, it exacerbates glomerular injury in vivo. Recombinant CCL5 and podocyte-specific CCL5 overexpression promoted cell survival and reduced apoptosis in cultured podocytes. However, in adriamycin-induced nephropathy, CCL5 worsened glomerular injury, increasing proteinuria, glomerulosclerosis, and podocyte loss. Bone marrow (BM) transplantation experiments revealed that CCL5 in BM-derived cells — not kidney-resident cells — drove disease progression. CCL5 deficiency in BM-derived cells conferred protection by increasing reparative M2 macrophages, whereas endogenous CCL5 promoted M1 polarization, inhibited M2 differentiation, and triggered M2-to-M1 transition. These findings demonstrate that while CCL5 supports podocyte survival, its expression in BM-derived cells promotes inflammatory macrophage phenotypes and glomerular injury. The harmful immune effects of CCL5 in BM-derived cells outweigh its podocyte-protective role, highlighting the importance of cell-targeted strategies to mitigate kidney damage.
- 23 May 2025
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 37 (9) , 567-581
SLAMF6 regulates basal T cell receptor signaling and influences invariant natural killer T cell lineage diversity
Invariant natural killer T (iNKT) cells differentiate into at least three distinct subsets within the thymus, with each subset’s frequency varying considerably among mouse strains; however, the molecular mechanisms involved remain unclear. We herein report that iNKT cell lineage diversity results from the significant expansion of iNKT2 cells with limited T cell receptor (TCR) diversity in BALB/c mice and the selection of iNKT1 cells with significantly diverse TCRs in B6 mice. Furthermore, signaling lymphocytic-activation molecule family 6 (SLAMF6) expression on immature thymocytes significantly differs among mouse strains, with the low expression of SLAMF6 on BALB/c immature thymocytes resulting in high “basal TCR signaling” in preselected DP thymocytes, associated with iNKT cell expansion. Our data suggest that the expression level of SLAMF6 on immature thymocytes affects basal TCR signaling in preselected DP thymocytes, which may influence thymocyte development in a T-cell subset.
- 23 May 2025
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 37 (9) , 567-581
SLAMF6 regulates basal T cell receptor signaling and influences invariant natural killer T cell lineage diversity
Invariant natural killer T (iNKT) cells differentiate into at least three distinct subsets within the thymus, with each subset’s frequency varying considerably among mouse strains; however, the molecular mechanisms involved remain unclear. We herein report that iNKT cell lineage diversity results from the significant expansion of iNKT2 cells with limited T cell receptor (TCR) diversity in BALB/c mice and the selection of iNKT1 cells with significantly diverse TCRs in B6 mice. Furthermore, signaling lymphocytic-activation molecule family 6 (SLAMF6) expression on immature thymocytes significantly differs among mouse strains, with the low expression of SLAMF6 on BALB/c immature thymocytes resulting in high “basal TCR signaling” in preselected DP thymocytes, associated with iNKT cell expansion. Our data suggest that the expression level of SLAMF6 on immature thymocytes affects basal TCR signaling in preselected DP thymocytes, which may influence thymocyte development in a T-cell subset.